Pharma and healthcare: sector news on Thursday 19 November 2026
Average tone +2.7 (slightly positive) across 5 companies with relevant coverage, from 36 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +5.5 | 23 | Coverage was mainly about the extended Tempus AI data agreement, US approval of a new Imfinzi bladder cancer regimen and a letter of intent between its Indian arm and Strand Life Sciences. |
| Haleon | −1.7 | 5 | Coverage was mixed: shares fell after a lowered analyst target and a Zacks downgrade prompted valuation questions. |
| Convatec | +10.0 | 4 | Coverage centred on Convatec lifting its revenue growth forecast, with shares jumping around 10%. |
| Smith & Nephew | −2.0 | 3 | Coverage centred on a guidance cut that sent the shares lower and put the orthopaedics business under scrutiny. |
| GSK | 0.0 | 1 |
Strongest stories in the sector
- +10.0 Sharp share price jump after improved sales guidance.
- +10.0 Higher sales growth guidance driven by strength in two product areas.
- +10.0 Broker endorsement sees more room for shares to rise.
- −9.7 Share price fell after the firm lowered its outlook; orthopaedics under scrutiny.
- +9.2 Broker supportive and sees long-term revenue ambition as achievable.
- +8.3 Regulatory clearance for new use of key cancer drug.
- +8.3 Approval of new bladder cancer treatment regimen.
- +7.5 Shares recovering following better-than-expected results.
- +7.5 Valuation commentary sees shares reasonable given brighter sales expectations.
- +7.0 Health programme with partner shows strong results, good for reputation.
- +7.0 Barclays lifted its price target, signalling analyst optimism on the shares.
- +6.7 Shares gained after the Indian tie-up news.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.